German Precision Cancer Think Tank
The Precision Cancer Consortium (PCC) will foster collaboration to improve global patient access to comprehensive genomic testing.
The Precision Cancer Consortium (PCC) will foster collaboration to improve global patient access to comprehensive genomic testing.
The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.
PCC-176, Date of Review: May 2025
